Agios shareholders elect two directors, approve 2.5M share plan increase and say-on-pay

AGIOS PHARMACEUTICALS, INC.

Class III directors Jacqualyn A. Fouse and David Scadden elected with 45.96M and 46.20M votes for, respectively.
Non-binding say-on-pay approved: 46.84M for, 3.02M against, 16,430 abstain.
2023 Stock Incentive Plan amendment approved: 31.68M for, 18.20M against (36.5% opposition), adding 2.5M authorized shares.
Ratification of PricewaterhouseCoopers as auditor: 51.20M for, 136,734 against, 22,781 abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.